Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People with a specific type of aortoiliac artery blockage or narrowing (classified under a system called TASC-II as modified class A, B, C, or D — confirm with trial site)
- People with a Rutherford score of 2 to 5, which is a scale used to measure how severely reduced blood flow is affecting the legs (confirm with trial site)
- People whose blood vessel access point is physically compatible with the medical device used in this trial
- People whose condition fits within the instructions for how the device is meant to be used
- People who are able to attend all required follow-up appointments for the full duration of the study
- People who have been fully informed about the study, agree to its terms, and have signed a consent form
Who may not be able to join:
- People with a known allergy or sensitivity to heparin, contrast dye, or the materials used in stents
- People with a blood disorder or disease affecting the blood (confirm with trial site)
- People who are pregnant or breastfeeding
- People currently taking part in another clinical trial involving an investigational drug or medical device
- People currently receiving chemotherapy or radiation therapy
- People who already have a stent or graft in the leg being treated
- People who had angioplasty or bypass surgery in the 30 days before joining the study
- People with a life expectancy of less than 12 months
- People who are unable to take a two-drug blood-thinning treatment known as dual antiplatelet therapy (DAPT)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fabio Cypreste Oliveira, Hospital Santa Helena
Phone: +55 (17) 2136-7005
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Device-Related Serious Adverse Events (Device Safety); Number of Patients with Technical Success (Device Performance); Number of Patients Without Rupture or Dissection of the Treated Vessel (Combined Safety and Performance Outcome)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.